Prostate cancer (PCa) is the second most commonly diagnosed malignancy in men and has
an extremely heterogeneous clinical behaviour. The vast majority of PCas are hormonally …

Prostate cancer (PCa) is a major health care challenge in the developed world, being the
most common type of cancer in men in the USA [1] and most European countries [2] and the …

Prostate cancer (PCa) is a clinically heterogeneous disease and current treatment strategies
are based largely on anatomical and pathological parameters. In the recent past, several …

Prostate cancer (PCa) represents the most commonly non-cutaneous diagnosed cancer in
men worldwide and occupies a very wide area of preclinical and clinical research. Targeted …

While localised prostate cancer can be cured by local treatment,'high-risk'prostate cancer
often progresses to castration resistant disease and remains incurable with a dismal …

The purpose of this review is to provide information on the molecular basis of prostate
cancer biology and to identify some of the targets for therapy, and highlight some potential …

Prostate cancer (PCa) is by far the most commonly diagnosed cancer in men worldwide.
Despite sensitivity to androgen deprivation, patients with advanced disease eventually …

Corcoran NM & Gleave ME (2012) Histopathology60, 216–231 Targeted therapy in prostate
cancer The therapeutic approach to advanced prostate cancer has seen greater changes in …

Creating a diagnostic, prognostic, and therapeutic treatment strategy precisely tailored to
each patient's requirements is the fundamental idea behind precision medicine. The …

Prostate cancer (PC) is the most frequently diagnosed cancer and the second leading cause
of cancer-related death in men in the Western society. Unfortunately, although the vast …